M0003 add-on therapy for persistent GERD symptoms despite proton pump inhibitors

Phase 2, randomised, double-blind trial in gastroesophageal reflux disease (GERD) comparing M0003 + proton pump inhibitor with Placebo + proton pump inhibitor (2 arms). Primary endpoints: Average number of liquid-containing reflux events per 24 hours, Average proximal extent of all liquid-containing reflux events in 24 hours and 1 more. Planned start Nov 2010; status: not yet recruiting.